ACE1831-001 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

NCT05653271

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

Associated Conditions

Bone Cancer

Principal Investigator

Sponsor

Acepodia

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of
ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies

This study is currently enrolling.